A substudy of the PLATO trial has shown that ticagrelor does not adversely affect pulmonary function in acute coronary syndrome (ACS) patients. This finding comes despite the increased incidence of dyspnea observed with ticagrelor in the main study, remark Robert Storey (University of Sheffield, UK) and co-authors in the American Journal of Cardiology.